Introduction
Hepatitis C virus (HCV) is the most destructive one among the blood borne pathogens and causes a major health issue worldwide. HCV remain endemic in many countries and infected about 170 million people around the globe [1] . The disease severity progresses from asymptomic condition to hepatocellular carcinoma through chronic infection and cirrhosis. Number of patients presenting long term complications of this infection is expected to increase in next 20 years as a protective vaccine against HCV does not yet exist and the therapeutic options remain limited [2] .
Eradication of virus is the main object of treatment against HCV defined by sustained virological response (SVR). Before the identification of hepatitis C virus in 1986 the beneficial functions of interferons (IFN) were well known in chronic hepatitis patients. A quick reduction of HCV RNA levels in serum was observed by IFN treatment, while long term responses became obvious with persistent loss of HCV RNA in serum [3] . Improvement in antiviral therapy increases the rate of SVR. In more than 40% patients antiviral therapy failed to control viral replication (non-responders) and there were also the cases of the infection reoccurrence after therapy was finished [4] . Various viral, host and social factors play the role in HCV response to the treatment. Host factors include age, gender, liver fibrosis stage, metabolic abnormalities and race [5, 6] while viral predictors are HCV genotype, plasma HCV RNA level and early viral kinetics on therapy [2, 3, 6] . Numerous factors are concerned in modifying the efficiency of interferon therapy against HCV infection [4] . Therefore, understanding of how these factors influence interferon therapy may identify therapeutic targets needed to improve the efficacy of interferon therapy [7] . Therefore it is of great importance to get insight into the mechanisms involved in non responsiveness and further to recognize the factors that can predict the likelihood of patient's response towards treatment. Hence, this review is attempted to summarize all the factors involved in HCV's lack of response to the treatment.
An evidence of acquisition
The required references were identified through searches in the Directory of Open Access Journals (DOAJ) Google Scholar, LISTA (EBSCO), Pubmed (NLM) and "web of knowledge" published in last 30 years by using the term "HCV and Interferone nonresponsivness", "HCV and treatment response" and "Factors associated with HCV non responsiveness". Articles resulting from these searches and relevant references cited in those articles were also reviewed.
Progression of HCV therapies

Interferon (IFN)
Naturally occurring IFNs exhibit diverse functions such as direct antiviral effect, stimulation of cytokine secretion, immune effector cells recruitment and initiation of cell segregation. Interferon α monotherapy was the only successful treatment available for chronic hepatitis patients until 1990. Antiviral effect of IFNs involved two separate but harmonizing mechanisms: (a) induction of an antiviral state that is not virus-specific in infected cells and consequently inhibits viral replication indirectly and (b) enhancement of host's specific antiviral immune responses by immune modulatory effects that might also speed up death of infected cells [8] . For human use several different kinds of IFNs have been approved by FDA. The US Food and Drug Administration (FDA) standardized 3 preparations of IFN for HCV treatment. (a) 3 million units (MUs) IFN-α-2a 3 times weekly; (b) 3 MUs of IFN-α-2b 3 times weekly; and (c) 9 gs of IFN alfacon-1 twice weekly, or 15 g 3 times weekly in non-responders [9] . In the beginning 3 weekly injections of 3MUs of IFN-α was approved for 6 month course against chronic hepatitis C (CHC) and serum ALT levels normalization was considered as main end point [10] . Higher doses and long term duration of IFN-α monotherapy enhanced the efficiency of therapy in CHC. However, frequency of SVR increased by about 20% when the therapy duration was prolonged to 12 months.
Peginterferon (PegIFN)
PegIFN is the conventional IFN with polyethylene glycol (PEG) added. These larger molecules possess longer half-life during biological activity, and permits more suitable dosage once a week. Two different types of PegIFNs and PegIFN-α-2a, branched molecule of 40 kDa bearing 80 hours (range: 50-140 hours) lethal half-life and a linear 12 kDa molecule PegIFN-α-2b possessing a mean terminal half--life of 40 hours (range: 22-60 hours). Both enhance the SVR rates in comparison with their non pegylated counterparts [11] .
The preliminary studies of PegIFN-α demonstrated the dose-dependent efficiency of monotherapy. Higher SVR rates were achieved at the dose 180 μg per week for 48 weeks for PegIFN-α-2a monotherapy when compared to IFN-α-2a monotherapy (30% to 39% versus 8% to 19%). Moreover, it was suggested that the treatment with PegIFN alone was well accepted and successful in cirrhotic CHC patients as well, with 30% SVR. PegIFN monotherapy is usually recommended for patients that cannot use ribavirin, for instance those with renal insufficiency, hemoglobinopathies, and ischemic cardiovascular disease [12] .
Ribavirin
A synthetic guanosine analogue, ribavirin, when used alone enhances the primary response, i.e., the ratio of patients that respond to the therapy, and distinctly declines the rate of relapse in these patients. Ribavirin potentiates the immunomodulatory properties of IFN-α and supports the fact that the response predictors are the same for both IFN-α monotherapy and for combination of IFN-ribavirin [13] .
Combinations of IFN-α and ribavirin
Addition of ribavirin with IFN-α was a key step in CHC treatment. Two multicentered RCTs 12were performed in 1998 that compared the IFN-α-2b monotherapy for 24 and 48 weeks with those of IFN-α-2b plus ribavirin for 24 weeks follow-up after the end of therapy [14] . The observed SVR rates were 33% for 24 and 41% for 48 weeks of IFN-α-2b-ribavirin therapy while the observed SVR rates of 6% at 24 weeks and 16% at 48 weeks with IFN-α-2b monotherapy. Combination therapy is reported to reduce the rate of non-responsiveness by 26%. Mortality and morbidity rates have also shown to be non-significant during combination treatment. In 1998 for CHC patients the combination of IFN-α and ribavirin was recommended by FDA.
PegIFN-α plus ribavirin
Different clinical trials anticipated that combination of PegIFN-α and ribavirin might be more successful against HCV infection . Earlier two large RCTs were performed with preset durations of 48 weeks. The trial dosage of PegIFN-α-2b approved by FDA was 1.5 μg/kgfollowed with 0.8 g of ribavirin. That combination resulted in 54% to 56% response in mentioned trials. It is established from these trials that higher SVR rates could be attained by weekly administration of PegIFN-α plus oral ribavirin recommended twice a day as compared to the combination of IFN-α given three timed a week with ribavirin or by PegIFN-α monotherapy [15] .
HCV response to the therapy
Three generalized patterns involved in HCV treatment reaction to antiviral therapy are as follow: (i) sustained virological response (SVR) (ii) end-of treatment response and relapse and (iii) non-response. Other responses include rapid virologic response (RVR) i.e. clearance of HCV RNA at 4th week and early virologic response (EVR). During treatment removal of evident HCV RNA and its sustained absence till 6 months after the end of the therapy is known as sustained virological response. Several studies demonstrated robustness of SVR in over 95% of patients on long term follow up [3] . Treatment for a short time, insufficient or missing doses of ribavirin and extent of hepatic fibrosis and cirrhosis leads 20-25% of patients to transient response with relapse Longer course of treatment and higher doses lead to the SVR. Patients who never become HCV RNA negative are considered as non-responders to treatment, although titers might drop for the period of treatment [16] .
Virological responders considered in slower decline phase until untraceable circulating levels of virus directed a very rapid preliminary decline in viral level [16, 17] . Efficient suppression of replication is reflected by initial decrease and considerable drop in HCV RNA levels within the first 1-2 days after the preliminary IFN dose. About 90-99% decline occur in first phase followed the second phase response that usually occurs in consequence of viral infected cell removal and is measured by the rate of decline in HCV RNA levels.
Interferon pathway activation
Induction of host signaling pathways by HCV infection leads to IFN secretion, dsRNA is involved in induction of host signaling pathways. Single stranded RNA of HCV is converted to dsRNA by replication in the presence of RNA-dependent RNA polymerase NS5B. Two receptors i.e. toll like receptors 3 (TLR3) and cytosolic retinoic acid inducible gene I (RIG-I) like helicases are responsible for recognition of double-stranded RNA through cellular pattern recognition. Consequently, dsRNA stimulate the signaling of IFN by binding and activating TLR3 and further stimulating the chain of events [17] . Two transcription factors i.e. NFkB and AP-1 become activated through phosphorylation of IRF3 (Interferon regulating factor 3). Furthermore, phosphorylated IRF3 moves inside the nucleus to bind DNA and regulate the IFN-β expression by forming a dimer. IFN-β promoter stimulator 1 (IPS-1 or Cardif) get recruited by receptors such as RIG-I and Mda5 after the binding of dsRNA. Activation of IRF3, IRF7 and NFkB involves the role of IPS-1. IRF-7, after structuring a dimer and translocating into the nucleus provoke IFN α or β, while IRF-3 dimers coordinate with NFkB also stimulate IFN α/β. IFN α/β binds cell surface receptor and stimulate the Jak/ STAT signaling pathway which further activates the IFN-stimulated response elements and consequently induce the transcription of IFN α/β stimulated genes. Moreover, two additional proteins RNAse L and protein kinase R were also investigated to be involved in viral RNA degradation and further the inhibition of their translation [18] .
Immunomodulatory roles of IFN
IFN also interacts with adaptive and innate immune responses besides its direct antiviral actions. Proliferation of memory T-cell and prevention of T-cell apoptosis enhanced by Type-1 IFNs consequently excite the activation of natural killer cell and maturation of dendritic cell. Additionally it enhances the assembly of major histocompatibility complex (MHC) class-I and class-II peptides, and might also support a T-helper 1 (TH1) over a T-helper-2 (TH2) phenotype. IFN might also prevent the immune exhaustion and enhance the adaptive HCV-specific immune response besides the direct immune stimulation, by decreasing HCV RNA replication [19] .
Adaptive immune response to HCV infection is increased by type I IFN. Induction of type I IFN by immunoproteosome subunits stimulate antigen processing and further amplified the adaptive immune response. Antiviral effects of type I IFNs include both direct and indirect ways as it is reported to be involved in proliferation of memory T cells [20] , enhancement of dendritic cell differentiation [21] , and up-regulation of class I MHC expression on hepatocytes [22] .
Inhibition of IFN actions by HCV
Variation in the amino acid sequence of HCV nonstructural-protein 5A (NS5A) has been reported to be related with IFN-α sensitivity [23] . NS5A (also known as IFN-sensitivity determining region (ISDR) is a 40 amino acid region and patients with different mutations in this region achieve SVR more easily as compared to patients with less mutations. The biological basis for coupling of HCV NS5A region with non-response to IFN-α therapy was demonstrated by the binding of NS5A to Protein Kinase RNA-activated (PKR) and further its inactivation in vitro. This binding is dependent on the existence of ISDR and an extra 26 carboxyl--terminal amino acids of NS5A [24] . In a study Foy and colleagues [25] showed that phosphorylation and activation of a key effector of the IFN antiviral cascade, IRF-3 blocked the protease activity of NS3/4A. Additionally, NS3/4A protease activity interferes HCV-induced signaling of the IFN-α receptor by RIG-I and, moreover, HCV protease inhibition restores RIG-I function [26] . It suggests that the active sites of IFN mediators could cleaved by the HCV protease and hence the combination treatment via a serine--protease inhibitor and IFN-α may have signifi cant synergistic activity.
HCV pathogenesis and IFN
There are several mechanism followed by a pathogen to evade from host immune response. Hepatic tissue damage and molecular oncogenesis of hepatocellular carcinoma are clear examples of this mechanism. Hyper-variability of virus envelope protein fails the successful clearance of virus from patient's body and facilitates HCV to neutralize antibody. HCV core protein is reported to be involved in reducing the robustness of the host's immune response as it decreases the transcription of interferon induced antiviral genes [27] . Inhibition of amplifi cation loop of IFN might be harmed by HCV NS3/4A protease which otherwise can inhibit HCV replication. By inhibiting the HCV protease, the effects of HCV infection can be reversed. Thus, protease inhibitors might act as one of the most noteworthy potential therapeutic agents for HCV [28] (Figure 1 ).
Factors involved in IFN resistance
Various substantial efforts have been made over the past decade to better understand the factors that can be used to predict the viral response towards treatment. These factors involve various host and viral factors as well. Herein, we shed a light on different host, viral, molecular and other factors that affect the treatment response of virus.
Viral factors 4.1 Quasispecies and Sequence Diversity
Production of a quasispecies (closely related but genetically distinct variants) permits HCV to avoid the response to host defense and antiviral therapies. At least 90% nucleotide sequence homology resulted in two quasispecies [18, 29] . Therefore, HCV sensitivity to therapy is uneven as this 10% of genetic divergence can possibly create various viral variants with a diverse receptivity towards treatment. Moreover, HCV patients with small quasispecies sequence are more prone to attain SVR as compared to patients exhibiting high complexity and significant changes in the composition of quasispecies. It was described that HCV protein complex is more stabilized in non responders due to the presence of three fold more hydrophobic amino acids as compared to responders [30] . Alteration in some subgenomic regions of HCV has been associated with IFN treatment sensitivity. Any mutation in amino acid sequence of ISDR [23] and IFN/ ribavirin resistancedetermining region (IRRDR) is considerably related with higher SVR rates. These two regions are important to play a role in treatment response and that's why any mutation in these two regions might influence the response to IFN therapy.
Viral genotypes
HCV patients infected with different genotypes respond differently to IFN-α as genotype is one of the strongest predictive factors of SVR. HCV patients possessing genotype 2 and 3 demonstrate 65% while patients with HCV genotype 1 show 30% SVR rate [31] . Hence, while prescribing the standard IFN therapy the genotype of patients should be considered.
Viral load and kinetics
Treatment of chronic hepatitis C with pegylated interferon and ribavirin cures the infection in 30-90% of the patients depending on baseline parameters [6, 15, 32] . Several investigations reported that the treatment response of HCV to IFN is associated with initial viral load. The outcome of treatment can also be predicted by viral kinetics, like: decline in first phase [33] and after the following weeks [34] [35] [36] [37] [38] [39] . Patients with more than 800,000 UI/ml (2 millions of copies/ ml) are less susceptible to the treatment than patients with a less viral load. Therefore, 24 weeks treatment is recommended for patients infected with genotype 1, containing low baseline viral load and RVR while patients with genotype 3, elevated baseline viral load and without RVR may demand treatment for 48 weeks [40] [41] [42] [43] [44] [45] [46] [47] . Likewise, the treatment duration is reduced to 12-16 weeks from 24 weeks in patients with rapid response infected with genotype 2 and 3 [48] [49] [50] [51] . Viral kinetic is helpful tool when response rates are low. To foresee the possibility of achieving an SVR, the presence of an RVR, EVR or no significant decrease of viral load is helpful. Patients exhibiting RVR are prone to achieve an SVR (higher than 85%). However, patients with persistent viral load don't respond to the treatment [52] .
Host factors and treatment response
Treatment response of HCV is dependent on several host factors along with viral factors. Patient's age and gender, ethnic background, liver cirrhosis and steatosis and resistance to insulin or diabetes are the factors correlated to low response rate to combination treatment of PegIFN plus ribavirin.
Insulin resistance and diabetes
The probability to obtain the SVR is reduced by insulin resistance [53] . Treatment of PegIFN and ribavirin in patients with impaired fasting glucose and type 2 diabetes might lower the rate of SVR while it increases by using insulin-sensitizing agents such as Pioglitazone [54] . Insulin resistance is induced by HCV expression. The core protein is involved in inhibition of insulin receptor 1 (IRS1) activity via activation of the Januse Kinase pathway [55] . Another protein USP18 was reported in 2006 to be involved in modification of IFN pharmacokinetic. Therefore, nonresponse to IFN treatment is also correlated with high level of USP18 expression [56] . To limit the inhibitory effect and consequently to increase the rate of SVR the therapy targeting USP18 could be used in future.
Fibrosis and cirrhosis
Substitution of an injured liver tissue by a collagenous scar is termed as fibrosis. It is result of a sustained wound healing response and abnormal extension of fibrogenesis (connective tissue fabrication and deposition) while Cirrhosis is a complex stage of liver fibrosis that is accompanied by deformation of the hepatic vasculature. About 12.5% patients with 20-year history of hepatitis C are estimated to develop cirrhosis and cirrhotic liver disease [57] . Advanced fibrosis or early-compensated cirrhosis generally have lower response rates, they can be successfully treated and may achieve SVR [58] . However, the success of antiviral therapy diminishes in the fact of decompensated cirrhotic disease owing to the severity of adverse effects in severely ill patients [59] .
Race
Race is also a specific characteristic that inclined the HCV kinetics and drug pharmacokinetics. For example, African American HCV positive patients are less responsive to antiviral therapy than the non-Hispanic white population [59] . In a study of 401 HCV infected patients possessing genotype 1, PegIFN-α-2a-and RBV treatment induced SVR rates of 28% for African American patients while 52% for white patients [60] . Layden-Almer and colleagues [61] observed the slower decrease in first-phase viral RNA, slower elimination of infected cells and slighter declines in mean viral RNA during 1 month in white patients as compared to African Americans infected with genotype 1 suggesting that African Americans may have an impaired skill to inhibit viral assembly.
Age
Another factor, patient's age is correlated with response to PegIFN-α/RBV therapy in CHC. Usually, it is believed that younger individuals (usually < 40 years of age) respond better to IFN-α treatment than older person [62] . In the elderly population immunological suppression, chronic disease and concurrent medications adversely affect response and heighten the probability of adverse reactions to antiviral therapy. In a retrospective cohort study of 84 elderly patients of age 65 years with genotype 1b or high viral load, 30 patients (35.7%) receiving IFN monotherapy achieved SVRs. Eleven patients (13%) withdrew because of adverse events, and univariate analysis showed a higher likelihood of withdrawal owing to adverse events among those age >70 years than those with age <70. The likelihood of SVR was significantly lower among those with high baseline viraemia, advanced liver fibrosis and HCV genotype 1 [63] . Thus, advanced age alone reduces antiviral effectiveness, but the addition of viral and hepatic risk factors further worsen response.
Obesity
Obesity is also one of the potential obstacles in response to HCV treatment. According to a report about 20-37% of HCV-infected patients are obese [64] . The SVR is inversely correlated with body mass index. Serum leptin which is elevated in obese patients is also a predictor of antiviral treatment resistance in HCV infection with low viraemia [65] . Interaction between obesity and antiviral therapy response focuses on hepatic steatosis, as obesity is an autonomous risk factor for fatty liver disease [64, 66] and obesity-triggered inflammatory reaction that decreases response and impairs IFN absorption owing to high levels of subcutaneous fats.
Hepatitis C virus/Human immunodeficiency virus co-infection
HCV/ HIV co-infection is coupled with ample morbidity and mortality, including end-stage liver disease, which is the principal basis of death in the hospitalized HIV population. HCV antiviral therapies become more complicated with HIV co-infection. Patients receiving antiretroviral therapy suffer amplified adverse effects of IFN and RBV therapy, such as depression and anemia [66] . In a study among 89 HIV/ HCV-infected patients, 48 (53.9%) exhibited a negative plasma HCV RNA at the end of treatment with PegIFN-α-2b and RBV, but only 29 (32.6%) achieved SVRs 6 months after treatment discontinuation [67] .
Liver and kidney transplantation
Chronic HCV infection may cause graft re-infection in both liver and kidney transplantation as the virus is seeded from the bloodstream to the new graft [68] .
Response to HCV therapies is affected by orthotopic liver transplantation, with SVR rates of 20-30% [69] . A meta analysis of different 48 studies examined the safety and efficacy of both standard IFN and PegIFN in liver transplant recipients [70] . The overall SVR rates were 24% with IFN and RBV and 27% with PegIFN and RBV; discontinuation rates were 24 and 26%, and pooled rates of graft rejection were 2 and 5% respectively. The slight efficacy advantage for PegIFN was attenuated by the slight disadvantage in the rates of discontinuation and graft rejections. Adverse effects can prompt premature treatment discontinuation in up to 50% of patients [71] . HCV infection also increases the risk of death among dialysis patients up to 2.39 -fold [72] and increases mortality rates among transplant recipients [73] . IFN monotherapy is the treatment of choice in HCV positive dialysis patients awaiting transplantation [74] . Two metaanalyses found that IFN monotherapy produced SVR rates of 33-39% [75] . Importantly, virological relapse rates are very low in dialysis patients who achieve an SVR before transplantation. Pre-transplantation treatment may also prevent postoperative complications such as fibrosing cholestatic hepatitis [76] . However, routine antiviral therapy for patients after kidney transplantation is not recommended because of the risk of graft rejection [77] .
Lipid profiles
Lipid profiles and virological response to antiviral treatment were recently correlated in many studies.
In Japan an investigation on the lipid fractions (20 subfractions based on particle size) from 44 CHC patients demonstrated that high triglyceride (TG) and very low--density lipoproteins (VLDL) content were strongly predictive of a better response to treatment [78] .
Hepatic steatosis
Hepatic steatosis is commonly observed risk factor for disease progression in HCV infected patients [79] . Progression of steatosis is dependent on both host and viral factors, with the relative significance of both varying with HCV genotype. Particularly, patients infected with genotype 3, exhibited mostly virus induced severe steatosis. On the contrary, in those with non-genotype 3, steatosis is mainly coupled with host metabolic factors and correlate with body mass index (BMI) and central adiposity [80] . Different clinical trials showed that steatosis disrupts the response of patients to antiviral therapy [81] .
Menopause and response to antiviral treatment
A large group of 1000 female patients with compensated liver diseases from CHC who were receiving standard PegIFN-α/RBV treatment was performed for SVR predictors. The study described that menopause correlate with not only severe liver disease, high necro inflammatory features and a high rate of hepatic steatosis but also a low likelihood of SVR in the entire group and in a subgroup of HCV genotype 1 females, probably due to inflammatory factors: IL-6 and TNF-α, which modulate at menopause [82] . Despite being up-regulated in female patients, these cytokines underwent a further and significant increase at the time of menopause, both circulating and hepatic levels. Ongoing studies are assessing whether the use of hormonal replacement therapy is associated with improved SVRs.
Detection of molecular markers correlated to treatment response
To avoid the critical after effects and high cost of PegIFN plus ribavirin therapy and others, it is of great importance to recognize some molecular markers that can predict the patient's response to the treatment.
Variation at single nucleotide level and treatment response
Several genome wide scans have been performed to get insight into the molecular pattern coupled with IFN treatment response. Single nucleotide polymorphism (SNP) is a variation of one nucleotide in the whole genome that might occur in either coding or in non coding region and can affect the protein activity or expression. This interaction was studied in response of antiviral treatment in 523 patients of chronic hepatitis C receiving combination treatment of IFN and ribavirin [83] . Among the total, 350 patients behave as sustained responders, while 173 did not show any response. Six candidate genes playing important role in IFN pathway (ADAR, CASP5, ISCBP1, IFI44, PIK3CG and TAP2) were focused and 20 SNPs were identified. These findings robustly maintain the perception that pharmocodynamics of IFN treatment is affected by genotype of virus and IFI44, members of interferon stimulated genes (ISGs).
Transcript gene expression
HCV treatment response can also be determined by liver gene expression as response to PegIFN and ribavirin is affected by differential expression of genes directly and indirectly as ISGs expression up-regulation has been reported in non responders [84] . Many serum secreted molecules (cytokines) act as predictors of treatment response encoded by the up-regulated genes found between non responders and responders [85] . Preliminary expression of interferon dependent gene is helpful in perceiving the response rate to combination therapy of PegIFN and ribavirin. In an investigation included 68 patients it was demonstrated that SVR rate could be foreseen by the expression genes i.e. the signal transducer, activator of transcription-6 (STAT-6) and suppressor of cytokine signaling-1 in samples prior treatment. Study also showed that interferon-dependent genes expression can help to predict the possibility of achieving an SVR even after 24 h of treatment [52] .
Role of serum proteins in response to IFN treatment
Chemokines are related with endothelial cells and the extracellular matrix close to the site of their production, but their high levels have been reported in serum of HCV infected patients [86] . CXC ligand 9 (CXCL9) (monokine induced by IFNγ, MIG) reported to be related with hepatic sinusoidal endothelium in healthy liver and elevated in liver tissue of patients with end-stage HCV infection [87] . CXCL10 (IFNγ-inducible protein 10, IP-10) may be produced by hepatocytes, sinusoidal endothelial cells, lymphoid cells, and monocytoid cells in the infected liver [86] . Interestingly, it was established that during successful anti-HCV therapy the binding CXCL 10 and CXCL9 decreased while there is no effect on CXCL11 level [85] . In a protein based study the investigators compared the expression of serum proteins in 96 patients with chronic hepatitis C [88] . They used the logistic regression to presage the response to the treatment (PegIFN plus ribavirin in 89% of all patients) and identified two protein peaks.
MicroRNAs and HCV infection
A class of RNA molecule that is non-coding and comprises 20-22 nucleotides called MicroRNAs (miRNAs), target the messenger RNA to inhibit the transcription by controlling the gene expression. They regulate the critical cellular pathways like development, cell division, proliferation and cell death. In addition to targeting the viral RNA directly, miRNAs can also exert an antiviral effect by modulating (directly or indirectly) the expression of cellular genes that suppress or facilitate viral replication. In HCV replication the role of miRNAs machinery has been recently investigated.
In liver tissue miRNA 122 correspond to about 70% of the miRNA. Furthermore, inhibition of HCV replication in Huh 122 hepatoma cells is associated with reduction of miRNA 122 [89] . It is suggested that binding of miR-122 stabilize the association of HCV mRNA with translation stimulating ribosomes [90] . These studies proposed that the presence of miR-122 in hepatocytes is beneficial for HCV; hence it can be use as a target for unique step in the management of HCV infection. Moreover, reduction of miR-122 expression by IFN-β supports the fact that cellular miRNA is being used to overcome the HCV infection by human organism. Another miRNA 199a has been reported in 2009 to be a strong regulator of HCV infection. HCV genome degradation is the target of miRNA 199a binding and it further limits the viral replication [91] . These studies suggest that inhibition of HCV might be mediated by miRNA and it may be possible to validate it for the improvement of novel anti-HCV therapies. The fact that several miRNAs can suppress HCV replication either through interaction with the HCV RNA or by modulating host factors that play a role in the viral life cycle may explain tropism restriction of the virus due to tissue specific miRNA content. Some of the reported miRNA has been summarized in Table 1 . 
Social factors
Non-cooperation of patient and false prescription of medication may act as inconsistent risk factors for treatment failure. Prohibited drug or alcohol abuse is allied with non-compliance, and severe events prompt treatment discontinuation in up to 14% of patients receiving PegIFN regimens [92] . The common, sporadic and remarkable adverse events have been seen with IFN and RBV. Similarly, incidence of psychiatric disorders (e.g. depression) prior to the start of treatment or consequential of treatment may compromise fulfillment and cause early treatment discontinuation [93] .
Provider factors
At the provider levels obstacles to HCV treatment may occur including primary care physicians and subspecialists. Key barriers to treatment include lack of knowledge and awareness, limited specialist availability and/or lack of referral and communication issues. Lack of information is associated with HCV prevalence, risk factors, anticipation and management [94] . Amongst primary care providers, a lack of experience is also a common factor. Further it is reported that primary care physicians rarely refer HCV patients for subspecialty assessment and only one-half of HCV infected patients are referred to a specialist for evaluation and management [95] . Boaz and colleagues [96] told that referral of HCV patients with normal liver tests is below 30%. Moreover, for those patients referred for treatment, the accessibility to specialists act as an additional hurdle. Efforts to increase the availability of specialist proficiency via telemedicine have shown some promise [97] . Additionally negative interaction of patients with treatment is also a barrier in HCV treatment.
In a cross-sectional study of 322 HCV patients treated at a tertiary care centre, 41% reported communication problems with their physicians [98] . Particularly, patients felt hasty, misinform or not listened to. Patients may question a physician's proficiency, or feel stigmatized by these interactions. Healthcare workers possess negative views of injection drug users, portray them as manipulative and obnoxious [94] . As a result of such interactions, patients may feel discouraged, less liable to listen to physician advices and more prone to defer therapy.
Hurdles at government and payer level
Governments and payers are important in providing HCV services, executing inspection plans, publicizing information and rising community plus provider awareness. Besides the patient and provider factors hurdles arise at government and payer level are equally important. In an international investigation on HCV provider's insufficient treatment promotion and lack of funding were considered important government level barriers [99] . Similarly, lack of insurance coverage, high out-of-pocket expenses and excessive paperwork were considered as payer-level barriers. To tackle these matters, amplified resource distribution and enhanced association among government, healthcare and educational stakeholders are required. In the European Union, government funded screening and surveillance agenda have greatly increased diagnosis rates of HCV infection [100] .
Conclusion and future recommendations
Drug resistance of hepatitis C is becoming a global burden these days. Various viral, host, environmental and social factors may influence disease. However, new drugs and treatment strategies should also be designed.
To reduce the present barriers to HCV treatment, it is required to recognize the contribution of cellular and antibody immune responses to viral clearance and further viral and host factors that prevent viral clearance.
Research in this field is obligatory to design the preventive and therapeutic measures to plan different treatment combinations that might help the immune response together with inhibition of viral replication.
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